Cutaneous Toxicities of <scp>MEK</scp> Inhibitor Use in Children: A Comparison of Binimetinib and Selumetinib
Our study confirms dermatologic adverse events are common in children on MEK inhibitors. Age appears to be associated with increased likelihood of certain cutaneous reactions. Overall, the selumetinib patients in our cohort presented with less severe adverse events and decreased risk of MEK inhibitor dose reduction/hold. Our results will aid clinicians in providing appropriate counseling, treatments, and improved preventive care.
Authors
- Soutrik Mandal (ORCID: https://orcid.org/0000-0002-0625-8999)
- Carli D. Needle (ORCID: https://orcid.org/0009-0002-9768-3831)
- Devorah Segal (ORCID: https://orcid.org/0000-0002-9740-1286)
- Lu Yin (ORCID: https://orcid.org/0000-0003-2537-8440)
- Kaleb Yohay (ORCID: https://orcid.org/0000-0001-5560-3392)
- Nikita Lakdawala (ORCID: https://orcid.org/0000-0002-8122-6145)
- Trevor K. Young (ORCID: https://orcid.org/0000-0003-0215-9886)
- Vikash S. Oza (ORCID: https://orcid.org/0000-0002-9102-0773)
- Steven G. Friedman
Institutions
- New York University (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Pediatric Dermatology
- Published
- 2024-11-07
- DOI
- https://doi.org/10.1111/pde.15792
- Citations
- 3
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.70